Clopipazan

CAS No. 60085-78-1

Clopipazan( —— )

Catalog No. M36149 CAS No. 60085-78-1

Clopipazan is an antipsychotic and antidepressant compound.Clopipazan has sedative and anxiolytic activity, possibly due to selective GABergic blockade of certain interneurons.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 167 Get Quote
5MG 257 Get Quote
10MG 380 Get Quote
25MG 615 Get Quote
50MG 873 Get Quote
100MG 1161 Get Quote
500MG 2322 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Clopipazan
  • Note
    Research use only, not for human use.
  • Brief Description
    Clopipazan is an antipsychotic and antidepressant compound.Clopipazan has sedative and anxiolytic activity, possibly due to selective GABergic blockade of certain interneurons.
  • Description
    Clopipazan is an antipsychotic and antidepressant compound.Clopipazan has sedative and anxiolytic activity, possibly due to selective GABergic blockade of certain interneurons.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    60085-78-1
  • Formula Weight
    311.81
  • Molecular Formula
    C19H18ClNO
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ClC=1C=C2C(C=3C(OC2=CC1)=CC=CC3)=C4CCN(C)CC4
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Isosilybin

    Isosilybin and Silybin might be suitable candidates to design potent PXR antagonists to prevent drug-drug interactions via CYP3A4 in cancer patients.

  • CCTA-1523

    CCTA-1523 is an efflux function of ABCG2 inhibitor. CCTA-1523 selectively reverses ABCG2-mediated MDR in cancer cells.

  • Citiolone

    Citiolone is a drug used in liver therapy. It is a derivative of the amino acid cysteine.